Preclinical Study of Therapeutic Efficacy of a New Russian Radiopharmaceutical 177Lu-DOTA-PSMA

V. K. Tishchenko,O. P. Vlasova,A. A. Lebedeva,A. V. Fedorova,A. A. Pankratov,N. B. Morozova,K. A. Kuzenkova,E. D. Stepchenkova,P. V. Shegai,S. A. Ivanov,A. D. Kaprin

Bulletin of Experimental Biology and Medicine（2024）

引用 0|浏览3

暂无评分

摘要

The therapeutic efficacy of a Russian radiopharmaceutical 177Lu-DOTA-PSMA was studied in vivo using male BALB/c nu/nu (nude) mice with prostate carcinoma 22Rv1 xenografts by tumor growth inhibition criterion. The mean tumor volumes in mice treated with 177Lu-DOTA-PSMA were significantly lower than in animals of the control group. There were no significant differences in the values of tumor growth inhibition between the groups of animals receiving 3.7 or 7.4 MBq of 177Lu-DOTA-PSMA.

查看译文

关键词

prostate-specific membrane antigen,metastatic castrate-resistant prostate cancer,radioligand therapy,lutetium-177,radiopharmaceutical

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要